A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-23. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
In 2002, Applied Biosystems reached revenues of US$1.6 billion for the year, and took control from Celera of the support of Celera Discovery System (CDS), a data tool to answer specific genomic and proteomic queries, involving the new genetic data field of tens of thousands of single-nucleotide polymorphisms (SNPs) within the human genome. The company developed another new tool, which combined the first ever union of triple quadrupole and ion trap technologies, in proteomics research. The database itself would remain with Celera, because of shareholder approval complications. Celera would retain responsibility for its maintenance and support to existing customers, and would receive royalties from Applied Biosystems. In 2003, Catherine Burzik joined Applied's management, from Ortho-Clinical Diagnostics. Applied developed a new tool which measured antibody/antigen binding in real-time kinetic analysis of up to 400 binding interactions simultaneously. In 2004, Mike Hunkapiller retired and Cathy Burzik replaced him as President of Applied Biosystems. Applera collaborated with General Electric, Abbott Laboratories, Seattle Genetics, and Merck in diagnostics development. Applied Biosystmes also teamed with Northrop Grumman and Cepheid of Sunnyvale, California, to detect Bacillus anthracis during the anthrax contamination case of the U.S. Postal Service. In 2005, the company released new tools for small molecule quantitation in pharmaceutical drug development.
Chris Heaton-Harris, the Secretary of State for Northern Ireland, announces the deadline to call the next Northern Ireland Assembly election would be extended until 8 February to allow the DUP to hold further talks about restarting the Northern Ireland Executive. 24 January – In a BBC interview, Conservative MP Simon Clarke calls for Rishi Sunak to be ousted as prime minister, then later says he is acting alone in his comments. Retired British Army officer Colonel Tim Collins is selected to run as the UUP candidate for North Down at the next general election. Andy Street, the mayor of the West Midlands, announces that he and his Manchester counterpart, Andy Burnham, are to meet Mark Harper, the Secretary of State for Transport, to discuss proposals for a privately funded alternative to the abandoned Manchester leg of HS2. 25 January – The UK has walked away from trade deal negotiations with Canada after failing to agree on how much access UK producers should have to the Canadian cheese market. 26 January – The Crown Prosecution Service has frozen assets belonging to former Conservative peer Michelle Mone and her husband Doug Barrowman, a spokesman for the couple says. Wales's Education Minister, Jeremy Miles, criticises the way Wales' largest trade union, Unite, declared its preferred candidate for the Welsh Labour leadership election. The union held a hustings with the two candidates before announcing its support for Vaughan Gething.
== Development == Cry of Fear began development in 2008. The mod was delayed several times due to time limitations before being released in 2012. During the 4 years of development time, many ideas were scrapped while others were improved. For example, the phone's flashlight was initially made to illuminate an area around the player. This was later changed to illuminate the area in front of the player. The inventory system was also reduced from 12 slots to 6. At its beginning, Cry of Fear used the standard Half-Life renderer which was later replaced by one from Paranoia, another popular Half-Life modification. Changing the renderer allowed the developers to bypass some older limits and add new engine effects such as texture bump mapping, specular reflection and 3D skyboxes. The game uses entirely custom assets and includes animated cutscenes.
=== Distribution === Estradiol is rapidly distributed throughout the body, with a distribution phase of about 6 minutes following intravenous injection. Estradiol is taken up into cells via passive diffusion due to its lipophilicity. Due to binding to the ERs, estradiol is preferentially concentrated in tissues with the highest ER content. In animals, these tissues have included the uterus, vagina, mammary glands, pituitary gland, hypothalamus, other brain regions, adipose tissue, liver, and adrenal glands, among other tissues. In contrast to estradiol, due to its low affinities for the ERs, estrone is not accumulated in target tissues. Estradiol has been found to cross the blood–brain barrier in rhesus monkeys. The volume of distribution of estradiol has been found to be 0.85 to 1.17 L/kg. In another study however, its volume of distribution was only 0.082 ± 0.015 L/kg (4.8 L in women of average weight 58.4 kg). In terms of plasma protein binding, estradiol is bound loosely to albumin and tightly to SHBG, with approximately 97 to 98% of estradiol bound to plasma proteins. In the circulation, approximately 38% of estradiol is bound to SHBG and 60% is bound to albumin, with 2 to 3% free or unbound. However, with oral estradiol, there is an increase in hepatic SHBG production and hence SHBG levels (e.g., +50%), and this results in a relatively reduced fraction of free estradiol. As only free estradiol that is not bound to plasma proteins or SHBG is biologically active, this may reduce the potency of oral estradiol by some degree.
Sources: en.wikipedia.org
=== Local Intelligence Unit === Post 2014 Burdwan blast, which unearthed Bangladesh-based militant group Jamaat-ul-Mujahideen Bangladesh, middle-east's terrorist group Islamic State and Pakistan's Inter-Services Intelligence terror module, the need for strengthening the local intelligence gathering mechanism was first felt. Following the incident the state govt has set up a new intelligence agency to counter terrorism, bust terror modules and invigilate suspicious movements in West Bengal and also to foil militant infiltration into the state.
The two substrates of this enzyme are testosterone and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are androstenedione, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3alpha(or 17beta)-hydroxysteroid:NAD+ oxidoreductase. Other names in common use include 3alpha,17beta-hydroxy steroid dehydrogenase, 3alpha(17beta)-HSD, and 3alpha(17beta)-hydroxysteroid dehydrogenase (NAD+). This enzyme participates in androgen and estrogen metabolism.
== Multi domain proteins == The adhesome contains multi domain proteins with various functions, some of which are specifically enriched in the adhesome compared to the cell proteome. Protein domains enriched in the adhesome include: Pleckstrin homology (PH) and FERM domains, which target proteins to the plasma membrane; Calponin homology (CH) domain, which is an F-actin binding motif; Src homology 2 (SH2) domain, which mediate interaction with phosphorylated tyrosine residues; armadillo (ARM) GUK and LIM domains, which mediate specific protein-protein binding. The literature-based adhesome contains enzymes, such as protein tyrosine and serine/threonine kinases and phosphatases, guanine nucleotide exchange factors and GTPase activating proteins, E3-ligases and proteases, that regulate adhesion through post translational modification of the many structural and scaffolding proteins found in the adhesome. The proteomic-based studies have identified many proteins from functional groups that haven't previously been associated with cell adhesion sites, such as proteins involved in RNA splicing, translation, trafficking, golgi, endoplasmic reticulum, and metabolic enzymes. Whether these proteins are indeed an integral part of the adhesome or an artifact of the proteomic methods remains to be seen.
Sources: en.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.